Bristol-Myers Squibb to present liver disease study data

Bristol-Myers Squibb is to present data on a number of new treatments for liver diseases at a forthcoming medical conference.

The company will be attending the American Association for the Study of Liver Diseases in order to highlight the progress made in recent clinical trials for drugs addressing conditions such as hepatitis B and C.

Among the presentations will be new results from a study of the chronic hepatitis B treatment Baraclude, as well as the earlier-stage compounds BMS-790052 and BMS-650032.

In addition, it will showcase phase IIa data for PEG-Interferon lambda, an agent produced by Bristol-Myers Squibb's development partner and future subsidiary ZymoGenetics.

Dr Elliott Sigal, executive vice-president, chief scientific officer and president for research and development at Bristol-Myers Squibb, said: "The data at this year's liver meeting demonstrates the breadth and strength of our hepatitis C portfolio."

Last month, the company published phase III study data for its diabetes drug dapagliflozin, demonstrating its efficacy when used in combination with metformin.